FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FGEN
CUSIPN/A
Phone415-978-1200
Debt
Debt-to-Equity Ratio0.19
Current Ratio7.95
Quick Ratio7.95
Price-To-Earnings
Trailing P/E Ratio-35.09
Forward P/E Ratio-45.98
P/E GrowthN/A
Sales & Book Value
Annual Sales$125.67 million
Price / Sales40.73
Cash FlowN/A
Price / CashN/A
Book Value$7.09 per share
Price / Book8.56
Profitability
EPS (Most Recent Fiscal Year)($1.73)
Net Income$-126,200,000.00
Net Margins-85.59%
Return on Equity-22.60%
Return on Assets-14.12%
Miscellaneous
Employees423
Outstanding Shares84,330,000
Market Cap$5.06 billion
FibroGen (NASDAQ:FGEN) Frequently Asked Questions
What is FibroGen's stock symbol?
FibroGen trades on the NASDAQ under the ticker symbol "FGEN."
How were FibroGen's earnings last quarter?
FibroGen Inc (NASDAQ:FGEN) posted its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.31. The biopharmaceutical company earned $43.95 million during the quarter, compared to analyst estimates of $28.70 million. FibroGen had a negative net margin of 85.59% and a negative return on equity of 22.60%. View FibroGen's Earnings History.
When is FibroGen's next earnings date?
What price target have analysts set for FGEN?
5 equities research analysts have issued 1-year target prices for FibroGen's stock. Their predictions range from $71.00 to $88.00. On average, they anticipate FibroGen's share price to reach $77.60 in the next twelve months. This suggests a possible upside of 27.8% from the stock's current price. View Analyst Price Targets for FibroGen.
What is the consensus analysts' recommendation for FibroGen?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for FibroGen.
What are Wall Street analysts saying about FibroGen stock?
Here are some recent quotes from research analysts about FibroGen stock:
- 1. Mizuho analysts commented, "We see the roxadustat program as highly de-risked and commercial risks are primarily born by partners." (8/8/2018)
- 2. According to Zacks Investment Research, "FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California. " (7/10/2018)
Who are some of FibroGen's key competitors?
Some companies that are related to FibroGen include Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Valeant Pharmaceuticals (VRX) and Bausch Health Companies (BHC).
Who are FibroGen's key executives?
FibroGen's management team includes the folowing people:
- Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 64)
- Mr. Pat Cotroneo, Chief Financial Officer (Age 54)
- Dr. K. Peony Yu, Chief Medical Officer (Age 56)
- Mr. Julian N. Stern, Sec. (Age 93)
- Dr. Barry A. Berkowitz, Founder
When did FibroGen IPO?
(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.
Has FibroGen been receiving favorable news coverage?
News headlines about FGEN stock have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. FibroGen earned a daily sentiment score of 0.07 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 47.58 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for FibroGen.
Who are FibroGen's major shareholders?
FibroGen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (10.13%), BlackRock Inc. (7.40%), Hillhouse Capital Management Ltd. (3.19%), Janus Henderson Group PLC (1.65%), First Trust Advisors LP (1.44%) and Eagle Asset Management Inc. (1.16%). Company insiders that own FibroGen stock include Gerald Lema, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.
Which institutional investors are selling FibroGen stock?
FGEN stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Bank of Nova Scotia, Millennium Management LLC, Pinnacle Associates Ltd., PNC Financial Services Group Inc., Dimensional Fund Advisors LP, Alps Advisors Inc. and Alps Advisors Inc.. Company insiders that have sold FibroGen company stock in the last year include James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff and Thomas F Kearns Jr. View Insider Buying and Selling for FibroGen.
Which institutional investors are buying FibroGen stock?
FGEN stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, PointState Capital LP, Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, BlackRock Inc., Jennison Associates LLC, First Trust Advisors LP and Eagle Asset Management Inc.. View Insider Buying and Selling for FibroGen.
How do I buy shares of FibroGen?
Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is FibroGen's stock price today?
One share of FGEN stock can currently be purchased for approximately $60.70.
How big of a company is FibroGen?
FibroGen has a market capitalization of $5.06 billion and generates $125.67 million in revenue each year. The biopharmaceutical company earns $-126,200,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. FibroGen employs 423 workers across the globe.
How can I contact FibroGen?
FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]
MarketBeat Community Rating for FibroGen (NASDAQ FGEN)
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe FGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
